Track topics on Twitter Track topics that are important to you
Regeneron Pharmaceuticals Inc's quarterly profit handsomely beat estimates on strong demand for its flagship Eylea drug, prompting the U.S. drugmaker to raise its full-year growth forecast for the eye treatment. Sales of Eylea, which is used to treat macular degeneration and other eye disorders that cause age-related vision loss, came in at $919 million and beat analysts' estimates, helped by higher demand as the U.S. population ages.
Original Article: UPDATE 3- Eylea helps Regeneron smash profit estimatesNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...